Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue GuidanceGlobeNewsWire • 01/13/20
Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)GlobeNewsWire • 01/13/20
Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) DeficiencyGlobeNewsWire • 01/09/20
Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty PharmaGlobeNewsWire • 12/18/19
Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/19
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation DisordersGlobeNewsWire • 10/14/19
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)GlobeNewsWire • 09/30/19
Ultragenyx Pharmaceutical And Ultra-Rare Diseases: A Voice For The Clinically UnderservedSeeking Alpha • 09/23/19
Ultragenyx Pharmaceuticals And Ultra-Rare Diseases: A Voice For The Clinically UnderservedSeeking Alpha • 09/23/19
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)GlobeNewsWire • 09/10/19
Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type IaGlobeNewsWire • 09/04/19
GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102GlobeNewsWire • 09/03/19
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/31/19